Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Raphael Reports Positive Cannabinoid Therapy Results for Arthritis
Details : Company’s cannabinoid-based formula is being investigated for the management of rheumatoid arthritis (RA).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enlivex Doses First Patient in Allocetra Phase 1 Psoriatic Arthritis Clinical Trial
Details : Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state in patients with psoriatic arthritis.
Product Name : Allocetra-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Allocetra-OTS
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avoplacel
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients. PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a fav...
Product Name : PLX-R18
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 23, 2022
Lead Product(s) : Avoplacel
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nebokitug
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The findings support the role of CCL24 as a potential therapeutic target, demonstrating elevated serum levels of CCL24 in patients with dcSSc. High CCL24 serum levels were correlated with disease activity and worse prognosis as reflected.
Product Name : CM-101
Product Type : Antibody
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Nebokitug
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ApoGraft
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company has entered into an international consortium of companies to examine the therapeutic effects of stem cells on the reduction of pulmonary manifestations caused by COVID-19.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : ApoGraft
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable